MX2023005678A - Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas. - Google Patents

Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas.

Info

Publication number
MX2023005678A
MX2023005678A MX2023005678A MX2023005678A MX2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A MX 2023005678 A MX2023005678 A MX 2023005678A
Authority
MX
Mexico
Prior art keywords
sup
factor receptor
cyclopentathiophen
antagonists
platelet activation
Prior art date
Application number
MX2023005678A
Other languages
English (en)
Spanish (es)
Inventor
Dieter Wiedenmayer
Matthias Eckhardt
Leo Thomas
Juergen Prestle
Marina Kristina Willwacher
Ferenc Kontes
Christofer Siegfried Tautermann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2023005678A publication Critical patent/MX2023005678A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
MX2023005678A 2020-11-16 2021-11-12 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas. MX2023005678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207719 2020-11-16
PCT/EP2021/081459 WO2022101377A1 (en) 2020-11-16 2021-11-12 Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Publications (1)

Publication Number Publication Date
MX2023005678A true MX2023005678A (es) 2023-05-26

Family

ID=73543025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005678A MX2023005678A (es) 2020-11-16 2021-11-12 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activacion de plaquetas.

Country Status (20)

Country Link
US (2) US11766443B2 (enExample)
EP (1) EP4244229A1 (enExample)
JP (3) JP7465368B2 (enExample)
KR (1) KR20230109692A (enExample)
CN (2) CN116745300A (enExample)
AR (1) AR124070A1 (enExample)
AU (1) AU2021379248A1 (enExample)
CA (1) CA3200710A1 (enExample)
CL (2) CL2023001361A1 (enExample)
CO (1) CO2023005894A2 (enExample)
CR (2) CR20230211A (enExample)
DO (1) DOP2023000090A (enExample)
EC (1) ECSP23036210A (enExample)
IL (1) IL302769A (enExample)
JO (1) JOP20230107A1 (enExample)
MX (1) MX2023005678A (enExample)
PE (1) PE20231855A1 (enExample)
SA (1) SA523440809B1 (enExample)
TW (1) TWI913356B (enExample)
WO (1) WO2022101377A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119842821A (zh) * 2025-01-06 2025-04-18 华中科技大学 稳定表达血小板活化因子受体的细胞株、构建方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502392A1 (de) 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
DD265405A5 (de) * 1986-01-21 1989-03-01 Boehringer Ingelheim Kg,De Neue thieno-1,4-diazepine
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
EP0368175A1 (de) 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
DE3909012A1 (de) 1989-03-18 1990-09-20 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
JP2959598B2 (ja) 1990-10-12 1999-10-06 吉富製薬株式会社 光学活性なチエノトリアゾロジアゼピン化合物
CN1033327C (zh) 1991-04-23 1996-11-20 东丽株式会社 三环三唑并衍生物的制造方法
DE4132763A1 (de) 1991-10-02 1993-04-08 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
US7749996B2 (en) 2006-11-20 2010-07-06 Alantos Pharmaceutical Holdings, Inc. Heterotricyclic metalloprotease inhibitors

Also Published As

Publication number Publication date
US20220160725A1 (en) 2022-05-26
CL2024000317A1 (es) 2024-07-12
AU2021379248A1 (en) 2023-06-22
TW202237620A (zh) 2022-10-01
CN117624188B (zh) 2026-08-07
JP7465368B2 (ja) 2024-04-10
CN117624188A (zh) 2024-03-01
PE20231855A1 (es) 2023-11-21
DOP2023000090A (es) 2023-06-15
JP7810743B2 (ja) 2026-02-03
CA3200710A1 (en) 2022-05-19
CO2023005894A2 (es) 2023-05-29
EP4244229A1 (en) 2023-09-20
CN116745300A (zh) 2023-09-12
JP2026090284A (ja) 2026-06-02
AU2021379248A9 (en) 2024-10-10
US11766443B2 (en) 2023-09-26
JP2023521200A (ja) 2023-05-23
ECSP23036210A (es) 2023-06-30
IL302769A (en) 2023-07-01
CR20230211A (es) 2023-07-13
SA523440809B1 (ar) 2024-10-08
WO2022101377A1 (en) 2022-05-19
US20230355638A1 (en) 2023-11-09
JOP20230107A1 (ar) 2023-05-16
KR20230109692A (ko) 2023-07-20
TWI913356B (zh) 2026-02-01
CL2023001361A1 (es) 2023-11-03
CR20260053A (es) 2026-03-24
JP2024099528A (ja) 2024-07-25
AR124070A1 (es) 2023-02-08

Similar Documents

Publication Publication Date Title
EA202191498A1 (ru) 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
MX2024001849A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
UY38766A (es) Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades
ATE329596T1 (de) Phthalazinderivate zur behandlung von entzündlicher erkrankungen
AR112099A1 (es) Imidazopirimidinas diazabicíclicas sustituidas y su uso
EA200870360A1 (ru) Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине
UY38765A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades
JP2017524733A5 (enExample)
PE20151559A1 (es) Nuevos derivados de piridina
CR20220382A (es) Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática
MX2023010317A (es) Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
DE60312042D1 (de) Substituierte 1-piperidin-4-yl-4-azetidin-3-yl-piperazinderivate und deren verwendung als neurokininantagonisten
RU2018106498A (ru) Производные 5-(N-конденсированный трициклический арил-тетрагидроизохинолин-6-ил) пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека
MX392990B (es) Compuestos, proceso de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de trastornos psiquiatricos y/o trastornos del sueño.
ECSP22035103A (es) Inhibidores de los receptores a2c adrenérgicos
SA520420487B1 (ar) مركبات ومستحضر صيدلاني من أزابنزيميدازول
CL2018002095A1 (es) Un derivado de piridina representado por las formulas i a iii y una sal farmacéuticamente aceptable del mismo; procedimiento de preparación del derivado de piridina o la sal farmacéuticamente aceptable del mismo; composición farmacéutica y su uso para preparar un medicamento útil para la prevención o tratamiento de una enfermedad de crecimiento celular anómalo producida por una mutación ras.
CO5580823A2 (es) Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf
SA523440809B1 (ar) مشتقات سيكلو بنتا ثيوفين كربوكساميد كمضادات مستقبل عامل تنشيط الصفائح الدموية
MX388697B (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
MX2022012090A (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas del receptor de somatostatina 4 (sstr4).
MX2021016068A (es) Derivados de isoquinolinona como inhibidores de la proteina quinasa rock y usos del mismo.
JOP20230148A1 (ar) مشتقات إيميدازو بيريدين كمثبطات لـ irak4 واستخدامها في علاج أحد الأمراض
PH12022552956A1 (en) Luminally-acting n-(piperidin-4-yl)benzamide derivatives
MX2023005071A (es) Amidas de isoquinolina enlazadas a n como inhibidores de lrrk2, composiciones farmaceuticas y usos de las mismas.